Market Overview

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Tetraphase Pharmaceuticals, Inc. To Contact The Firm


Faruqi & Faruqi, LLP, a leading national securities law firm, reminds
investors in Tetraphase Pharmaceuticals, Inc. ("Tetraphase" or the
"Company") (NASDAQ:TTPH) of the September 25, 2018 deadline to seek the
role of lead plaintiff in a federal securities class action that has
been filed against the Company.

If you invested in Tetraphase stock or options securities pursuant
and/or traceable to the Company's July 2017 secondary public offering
("SPO") and/or between March 8, 2017 and February 13, 2018,
would like to discuss your legal rights, click
There is no cost or obligation to you.

You can also contact us by calling Richard Gonnello toll free at
or at 212-983-9330 or by sending an e-mail to

The lawsuit has been filed in the U.S. District Court for the Southern
District of New York on behalf of all those who purchased Tetraphase
securities pursuant and/or traceable to the Company's false
and/or misleading registration statement and prospectus issued in
connection with the Company's July 2017 SPO and/or between March 8, 2017
and February 13, 2018 (the "Class Period"). The case, Garity v.
Tetraphase Pharmaceuticals, Inc. et al.
, No. 18-cv-06797 was
filed on July 27, 2018.

The lawsuit focuses on whether the Company and its executives violated
federal securities laws by failing to disclose that: (1) it was
increasing the patient enrollment in its IGNITE3 trial of eravacyline in
complicated urinary tract infection from 1,000 patients to 1,200
patients to meet the trial's primary endpoints; and (2) the enrollment
of more patients in the trial indicated that the existing population was
inadequate to meet the trial's primary endpoints.

Specifically, on February 13, 2018, Tetraphase announced that its
IGNITE3 trial failed to achieve its co-primary efficacy endpoints.

On this news the announcement, TTPH's share price fell from $5.43 per
share on February 13, 2018 to a closing price of $2.15 on February 14,
2018—a $3.28 or a 60.41% drop.

The court-appointed lead plaintiff is the investor with the largest
financial interest in the relief sought by the class who is adequate and
typical of class members who directs and oversees the litigation on
behalf of the putative class. Any member of the putative class may move
the Court to serve as lead plaintiff through counsel of their choice, or
may choose to do nothing and remain an absent class member. Your ability
to share in any recovery is not affected by the decision to serve as a
lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding
Tetraphase's conduct to contact the firm, including whistleblowers,
former employees, shareholders and others.

Attorney Advertising. The law firm responsible for this advertisement is
Faruqi & Faruqi, LLP (
Prior results do not guarantee or predict a similar outcome with respect
to any future matter. We welcome the opportunity to discuss your
particular case. All communications will be treated in a confidential

View Comments and Join the Discussion!